cisplatin + paclitaxel + sorafenib

This is a combination regimen consisting of three anticancer agents—cisplatin, paclitaxel, and sorafenib—used in investigational settings for the treatment of various advanced solid tumors. - **Cisplatin** is a platinum-based chemotherapeutic that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. - **Paclitaxel** is a microtubule-stabilizing agent that inhibits cell division by preventing microtubule depolymerization. - **Sorafenib** is an oral multikinase inhibitor targeting several serine/threonine and receptor tyrosine kinases involved in tumor cell proliferation and angiogenesis (notably RAF kinases, VEGFRs, PDGFR). The rationale for combining these drugs lies in their complementary mechanisms of action; cisplatin and paclitaxel provide cytotoxic effects through DNA damage and mitotic arrest respectively, while sorafenib adds targeted inhibition of signaling pathways critical for tumor growth and vascularization[1][3][4][6]. This combination has been explored primarily in clinical trials for advanced cancers such as breast cancer (neoadjuvant setting), head and neck squamous cell carcinoma (with chemoradiation), gastric cancer (with docetaxel substituted for paclitaxel), testicular cancer (with carboplatin substituted for cisplatin), among others[2][3][6][8]. The triple regimen aims to enhance antitumor efficacy via synergistic or additive effects but may also increase toxicity risks.